GlassScriptPhysician profile
Ashley N Gattis
NPI 1063932283
$1,208.31
in general payments reported to CMS, 2019-2025
20 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.36 · 2022: $221 · 2023: $299 · 2024: $387 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.65 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.78 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $134.80 | 2022-2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $107.40 | 2022-2024 | Trelegy Ellipta |
| Abbott Laboratories | $83.64 | 2022-2024 | Freestyle Libre |
| Lilly USA, LLC | $53.97 | 2021-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $44.32 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $34.22 | 2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $34.18 | 2022-2023 | Rybelsus, Ozempic |
| Neurocrine Biosciences, INC. | $33.23 | 2023 | Ingrezza |
| Astellas Pharma US INC | $26.79 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.61 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $17.88 | 2022 | |
| Phadia US INC. | $17.71 | 2024 | Immunocap |
| Sumitomo Pharma America, INC. | $17.30 | 2024 | Gemtesa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16.59 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $15.37 | 2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $14.02 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.89 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Gattis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.